Abstract Details

Title Headache Claims-Based Prevalence and Healthcare Utilization among Healthcare Employees

Topic Headache

Presentation(s) P1 - Poster Session 1 (11:45 AM-12:45 PM)

Poster/Presentation
Number 12-006

Objective Assess headache claims-based prevalence and cost among employees of a healthcare organization

Background

Migraine is a leading cause of productivity loss in the workplace, which tends to be overlooked due to stigma and concealment, the fact that 89% of migraine-related productivity loss stems from presenteeism (vs absences), and the relative low headache claims. Raising headache awareness in the workplace sometimes comes with the fear of increasing diagnosis and hence evaluation and management costs to self-insured employers.

Design/Methods IRB-approved, retrospective study of one year of medical and pharmacy claims data of all employees (not their dependents) continuously enrolled on their employer health insurance plan. ICD10 codes were used to identify 1) claimants with headache disorders and 2) headache-related medical claims, 3) medications prescribed for headache.

Results In 2023, the claims-based prevalence of headache is 5.8% (945 of 16,395 continuously enrolled employees). The total medical and pharmacy costs per member per month (PMPM) of claimants with headache ($1,061 and $579, respectively) are higher than those of claimants without headache ($575 and $268). In terms of headache-related claims PMPM, the medical and pharmacy costs are $135 and $158, respectively. The headache-specific medical claims represent less than 1% of total cost to the employee health plan.

Conclusions Even in a healthcare organization, the claims-based prevalence of headache among employees is low (5.8%) compared to the prevalence of headache in the general population. The prevalence of migraine alone is 15.9%. Headache disorders are underdiagnosed and undertreated in the workplace. Consistent with prior studies, the total healthcare costs of headache claimants are higher than those of claimants without headache and the difference is not fully accounted for by headache-specific claims. The healthcare utilization (medical and pharmacy) cost of headache diagnosis and treatment represents a small fraction of total costs covered by the employee health plan.

Authors/Disclosures
Olivia Begasse De Dhaem, MD (Institute for Headache and Brain Health) PRESENTER	Dr. Begasse De Dhaem has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Begasse De Dhaem has received personal compensation in the range of $500-$4,999 for serving as a Consultant for JOGO. Dr. Begasse De Dhaem has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Begasse De Dhaem has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pain Medicine Journal. Dr. Begasse De Dhaem has received publishing royalties from a publication relating to health care.
Daod Pak, MD	Dr. Pak has nothing to disclose.
Brian Grosberg, MD (Hartford HealthCare Headache Center)	Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Linpharma pharmaceuticals. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Theranica . Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Grosberg has stock in Theranica. The institution of Dr. Grosberg has received research support from Theranica. The institution of Dr. Grosberg has received research support from Amgen. The institution of Dr. Grosberg has received research support from Abbvie. The institution of Dr. Grosberg has received research support from Eli Lilly. The institution of Dr. Grosberg has received research support from Teva. The institution of Dr. Grosberg has received research support from Neurolief. Dr. Grosberg has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��